RxDoctor Payments DataLook up a doctor →

Khawaja Jahangir, MD

Hematology & Oncology · Las Vegas, NVNPI 1184806663

Payments from drug & device makers

$2,506,671in general payments, 2019–2025

Across 533 payments — averaging $4702.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$853K
  • Merck$588K
  • Genentech, Inc.$223K
  • AstraZeneca$199K
  • Daiichi Sankyo Inc.$136K
  • Sanofi US Services Inc.$130K
  • plus $378K from 40 others
$2,767in research payments, 2019–2025

Across 2 payments — averaging $1383.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Daiichi Sankyo Inc.$2K
  • Eli Lilly$637

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Seagen Inc.161$853,082
Merck20$588,343
Genentech, Inc.36$222,821
AstraZeneca24$198,576
Daiichi Sankyo Inc.21$135,926
Sanofi US Services Inc.20$130,357
Astrazeneca UK Limited5$97,391
Pfizer48$93,789
Novocure Inc.21$66,757
Incyte Corporation18$35,686
Takeda Pharmaceuticals U.S.A., Inc.26$28,849
Regeneron20$19,549
Janssen Research & Development, LLC2$11,699
Karyopharm Therapeutics Inc.2$8,435
Astellas Pharma Inc1$6,040
Novocure GmbH6$5,400
Nestle Healthcare Nutrition Inc.2$1,465
Boston Scientific3$411
Amgen20$401
Novartis26$313
Gilead(2 entities)8$196
E.r. Squibb & Sons, L.L.C.7$131
Foundation Medicine, Inc.1$122
Johnson & Johnson3$116
Secura Bio, Inc.1$114
Medtronic1$87
Genentech USA, Inc.4$78
Ipsen Biopharmaceuticals, Inc1$67
Astellas Pharma US Inc3$49
Sobi, Inc1$43
Myovant Sciences Inc.2$40
Dendreon Pharmaceuticals LLC2$40
EMD Serono, Inc.2$35
Blueprint Medicines Corporation1$32
Adaptive Biotechnologies Corporation2$29
Coherus Oncology, Inc.1$26
Teva Pharmaceuticals USA, Inc.2$25
ADC Therapeutics America, Inc.1$23
Tempus AI, Inc1$22
Intuitive Surgical1$19
Global Blood Therapeutics, Inc.1$18
Exelixis Inc.1$17
Sanofi1$15
Bayer1$14
Array Biopharma Inc1$13
Helsinn Therapeutics (U.S.), Inc.1$11

How this compares

$2,506,671 in reported general payments places this provider in the 95th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024
$804,908
Medicare patients
170
Services billed
30,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →